Fulcrum Therapeutics, Inc. (FULC): Total Assets
$366.28M
As of 2025-12-31
$323.95M
As of 2026-06-30
+17.3%
3-year compound annual growth
+23.1%
5-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $366.28M | +40.5% | 2026-02-24, Balance as of period end |
| 2024-12-31 | $260.72M | +1.2% | 2026-02-24, Balance as of period end |
| 2023-12-31 | $257.69M | +13.7% | 2025-02-25, Balance as of period end |
| 2022-12-31 | $226.69M | -3.5% | 2024-02-27, Balance as of period end |
| 2021-12-31 | $235.00M | +81.4% | 2023-06-26, Balance as of period end |
| 2020-12-31 | $129.58M | +17.3% | 2023-06-26, Balance as of period end |
| 2019-12-31 | $110.44M | +28.8% | 2023-06-23, Balance as of period end |
| 2018-12-31 | $85.77M | n/a | 2020-03-05, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Fulcrum Therapeutics, Inc. (FULC) | 2025-12-31 | $366.28M | +40.5% |
| Abbott Laboratories (ABT) | 2025-12-31 | $86.71B | +6.5% |
| Bristol Myers Squibb Co (BMY) | 2025-12-31 | $90.04B | -2.8% |
| TherapeuticsMD, Inc. (TXMD) | 2025-12-31 | $37.66M | -3.0% |
| Eli Lilly & Co (LLY) | 2025-12-31 | $112.48B | +42.9% |
| Pfizer Inc (PFE) | 2025-12-31 | $208.16B | -2.5% |
| Johnson & Johnson (JNJ) | 2025-12-28 | $199.21B | +10.6% |
| Nature's Sunshine Products Inc (NATR) | 2025-12-31 | $261.15M | +8.4% |
| Merck & Co., Inc. (MRK) | 2025-12-31 | $136.87B | +16.9% |
Compare FULC, ABT, BMY, TXMD side by side · Screen every company in Pharmaceutical Preparations ↗